Ticker News
$HCWB News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
HCWB to do 1-for-6 reverse split effective June 30 to meet Nasdaq $1 bid rule
HCW Biologics (HCWB) will effect a 1-for-6 reverse stock split at 12:01 a.m. ET on June 30, 2026, reducing shares outstanding from ~9.58M to ~1.60M (new CUSIP 40423R303) and will continue trading under the HCWB symbol on Nasdaq. The split is intended to ensure compliance with Nasdaq’s $1 minimum bid-price rule and conditions set by a Nasdaq Hearings Panel (the company completed at least 20 trading days above $1 and reported 28 consecutive days above $1), and the company warns failure to maintain the bid will risk immediate delisting; no fractional shares will be issued—holders otherwise due fractions will receive one whole share.
HCWB Phase 1 readout: 3/3 in 3 µg/kg cohort showed ≥25% SALT improvement; no serious IL‑2 AEs
HCW Biologics (HCWB) announced preliminary Phase 1 data in alopecia areata: in the 3 µg/kg cohort (n=3, mild AA) all participants had ≥25% reduction in SALT score at 4 and/or 9 weeks after a single subcutaneous dose, and no dose‑limiting toxicities or serious IL‑2‑related adverse events were reported. The update signals an early safety/tolerability win and a small single‑dose efficacy signal, but is limited by very small cohort size, mild baseline disease, and ongoing higher‑dose and correlative analyses needed to confirm activity and define a Phase 2 dose (RP2D targeted by year‑end 2026).
HCWB S-1: Registration to Resell 5.693M PIPE shares/warrants (May 2026)
HCW BIOLOGICS INC. filed SEC Form S-1. The registration must be declared effective before the selling stockholders can sell these shares into the market; the company would receive up to approximately $3.6 million only if the common warrants are cash-exercised in full.
HCWB regains ex‑vivo rights to HCW9206/HCW9201; HCW9206 shows Tscm enrichment in preclinical data
HCW Biologics exercised its option to regain full ex vivo rights to two commercial-ready reagents, HCW9206 and HCW9201, from Wugen at no cost and retained the nonrefundable upfront license fee (including 2.2M Wugen shares); the company says it will commercialize the reagents via partners focused on CAR‑T and NK‑cell therapies. A recent Science Advances paper reported HCW9206 (a multi‑cytokine fusion reagent) generates CAR‑T cells enriched for long‑lived T‑memory stem (Tscm) cells and may lower manufacturing costs and improve persistence — findings are early/preclinical and company framing is forward‑looking.
HCW Biologics regains ex‑vivo rights to CAR‑T reagents HCW9206 & HCW9201
HCW Biologics (HCWB) exercised its option to regain full ex vivo commercial rights to two reagents, HCW9206 and HCW9201, from licensee Wugen at no additional cost while retaining the nonrefundable upfront fee and 2.2 million shares of Wugen common stock. The company cites peer‑reviewed data showing HCW9206 (an IL‑7/IL‑15/IL‑21 fusion) can enrich long‑lived T‑memory stem cells (Tscm), potentially lowering CAR‑T manufacturing costs and improving persistence/functionality, and plans to commercialize the reagents via partners focused on CAR‑T and NK‑cell therapies.